

参考文献:

- [1] FINN RS, QIN SK, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma [J]. *N Engl J Med*, 2020, 382(20): 1894-1905. DOI: 10.1056/nejmoa1915745.
- [2] REN ZG, XU JM, BAI YX, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2-3 study[J]. *Lancet Oncol*, 2021, 22(7): 977-990. DOI: 10.1016/S1470-2045(21)00252-7.
- [3] QIN SK, CHAN SL, GU SZ, et al. Camrelizumab plus rivo-ceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): A randomised, open-label, international phase 3 study[J]. *Lancet*, 2023, 402(10408): 1133-1146. DOI: 10.1016/S0140-6736(23)00961-3.
- [4] ZHU HD, LI HL, HUANG MS, et al. Transarterial chemoembolization with PD-(L)₁ inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001) [J]. *Signal Transduct Target Ther*, 2023, 8(1): 58. DOI: 10.1038/s41392-022-01235-0.
- [5] HE MK, LIANG RB, ZHAO Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J]. *Ther Adv Med Oncol*, 2021, 13: 17588359211002720. DOI: 10.1177/17588359211002720.
- [6] LIU D, MU H, LIU C, et al. Hepatic artery infusion chemotherapy (HAIC) combined with sintilimab and bevacizumab biosimilar (IBI305) for initial unresectable hepatocellular carcinoma (HCC): A prospective, single-arm phase II trial[J]. *J Clin Oncol*, 2022, 40(16 Suppl): 4073.
- [7] GU YK, ZHANG TQ, ZUO MX, et al. Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage c: a prospective, single-arm, phase II trial (TRIPLLET study) [J]. *J Clin Oncol*, 2022, 40(16 Suppl): 4106.
- [8] ZANG M, LI Q, PANG H, et al. Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study) [J]. *Ann Oncol*, 2022, 33: S874. DOI: 10.1016/j.annonc.2022.07.850.
- [9] ZHANG XY, ZHU X, FENG X, et al. 715P The safety and efficacy of lenvatinib combined with TACE and PD-1 inhibitors (Len-TAP) versus TACE alone in the conversion resection for initially unresectable hepatocellular carcinoma: Interim results from a multicenter prospective cohort study[J]. *Ann Oncol*, 2022, 33: S870. DOI: 10.1016/j.annonc.2022.07.839.
- [10] General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition) [J]. *J Clin Hepatol*, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版) [J]. *临床肝胆病杂志*, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
- [11] Clinical Diagnosis and Treatment Guidelines Committee of the Interventional Physicians Branch of the Chinese Medical Association. Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma[J]. 2021, 60(7): 599-614. DOI: 10.3760/cma.j.cn112137-20210425-00991.
中国医师协会介入医师分会临床诊疗指南专委会. 中国肝细胞癌经动脉化疗栓塞(TACE)治疗临床实践指南(2021年版) [J]. *中华内科杂志*, 2021, 60(7): 599-614. DOI: 10.3760/cma.j.cn112137-20210425-00991
- [12] LLOVET JM, DE BAERE T, KULIK L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma[J]. *Nat Rev Gastroenterol Hepatol*, 2021, 18(5): 293-313. DOI: 10.1038/s41575-020-00395-0.
- [13] KUDO M, HAN GH, FINN RS, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial [J]. *Hepatology*, 2014, 60(5): 1697-1707. DOI: 10.1002/hep.27290.
- [14] KUDO M, CHENG AL, PARK JW, et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): A randomised, double-blind, placebo-controlled, multicentre, phase 3 study[J]. *Lancet Gastroenterol Hepatol*, 2018, 3(1): 37-46. DOI: 10.1016/S2468-1253(17)30290-X.
- [15] GOLFIERI R, GIAMPALMA E, RENZULLI M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma[J]. *Br J Cancer*, 2014, 111(2): 255-264. DOI: 10.1038/bjc.2014.199.
- [16] HAN ZQ, YANG FJ, ZHANG Y, et al. Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study[J]. *Front Oncol*, 2022, 12: 1029951. DOI: 10.3389/fonc.2022.1029951.
- [17] WANG WJ, LIU ZH, WANG K, et al. Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study[J]. *Cancer Med*, 2023, 12(10): 11513-11524. DOI: 10.1002/cam4.5880.
- [18] YANG XG, SUN YY, WANG HQ, et al. Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis[J]. *Front Oncol*, 2022, 12: 914385. DOI: 10.3389/fonc.2022.914385.
- [19] LLOVET JM, VOGEL A, MADOFF DC, et al. Randomized phase 3 LEAP-012 study: Transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment[J]. *Cardiovasc Intervent Radiol*, 2022, 45(4): 405-412. DOI: 10.1007/s00270-021-03031-9.
- [20] GU SZ, TAN YL, HU HT, et al. Donafenib Toluensulfo-

- nate Tablets, Anti PD-1 Monoantibody Combined with Transcatheter Arterial Chemoembolization (TACE) for Non resectable Liver Cancer (uHCC) [C]. Nanjing: 2022 CSCO Academic Paper Compilation, Oral Report on Hepatobiliary Pancreatic Tumors: 24-25.
- 古善智, 谭玉林, 胡鸿涛, 等. 甲苯磺酸多纳非尼片、抗PD-1单抗联合经动脉化疗栓塞治疗(TACE)用于不可切除的肝癌(uHCC) [C]. 南京: 2022年CSCO学术论文汇编, 肝胆胰肿瘤口头报告: 24-25.
- [21] CAO YJ, ZHANG XB, SHI J, et al. Donafenib combined with transarterial chemoembolization(TACE)and camrelizumab as conversion therapy for initial unresectable hepatocellular carcinoma(HCC): A prospective, single-arm, single center, phase II clinical study[J]. Chin Clin Oncol, 2023, 28(6): 481-487. DOI: 10.3969/j.issn.1009-0460.2023.06.001.
- 曹亚娟, 张雪斌, 史炯, 等. 甲苯磺酸多纳非尼联合经肝动脉栓塞化疗(TACE)及卡瑞利珠单抗转化治疗初始不可切除的肝细胞癌: 一项前瞻性、单臂、单中心II期临床试验[J]. 临床肿瘤学杂志, 2023, 28(6): 481-487. DOI: 10.3969/j.issn.1009-0460.2023.06.001.
- [22] Professional Committee of Oncology Intervention, China Anti-Cancer Association; Sub-committee of Chemotherapy and Immunotherapy, Professional Committee of Oncology Intervention, China Anti-Cancer Association. Chinese expert consensus on the modified implantation technique of port-catheter system for percutaneous hepatic arterial infusion chemotherapy(version 2022) [J]. J Clin Hepatol, 2022, 38(11): 2462-2469.
- 中国抗癌协会肿瘤介入学专业委员会, 中国抗癌协会肿瘤介入学专业委员会化疗与免疫治疗分委会. 改良式经皮肝动脉化疗药盒植入技术中国专家共识(2022版) [J]. 临床肝胆病杂志, 2022, 38(11): 2462-2469.
- [23] ZHENG KL, ZHU X, FU SJ, et al. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: A randomized trial[J]. Radiology, 2022, 303(2): 455-464. DOI: 10.1148/radiol.211545.
- [24] HE MK, LI QJ, ZOU RH, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960. DOI: 10.1001/jamaoncol.2019.0250.
- [25] LAI ZC, HE MK, BU XY, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial[J]. Eur J Cancer, 2022, 174: 68-77. DOI: 10.1016/j.ejca.2022.07.005.
- [26] ZHANG W, GAO W, LIU C, et al. 999P Donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab for unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm phase II trial (DoHAICs study) [J]. Ann Oncol, 2023, 34: S613. DOI: 10.1016/j.annonc.2023.09.2143.
- [27] CHENG AL, QIN SK, IKEDA M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2022, 76(4): 862-873. DOI: 10.1016/j.jhep.2021.11.030.
- [28] REIG M, FORNER A, RIMOLA J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update[J]. J Hepatol, 2022, 76(3): 681-693. DOI: 10.1016/j.jhep.2021.11.018.
- [29] LEE YH, TAI D, YIP C, et al. Combinational immunotherapy for hepatocellular carcinoma: Radiotherapy, immune checkpoint blockade and beyond[J]. Front Immunol, 2020, 11: 568759. DOI: 10.3389/fimmu.2020.568759.
- [30] LUKE JJ, LEMONS JM, KARRISON TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors[J]. J Clin Oncol, 2018, 36(16): 1611-1618. DOI: 10.1200/JCO.2017.76.2229.
- [31] CHIANG CL, CHAN ACY, CHIU KWH, et al. Combined stereotactic body radiotherapy and checkpoint inhibition in unresectable hepatocellular carcinoma: A potential synergistic treatment strategy[J]. Front Oncol, 2019, 9: 1157. DOI: 10.3389/fonc.2019.01157.
- [32] CHEN YB, HONG HY, FANG WZ, et al. Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study[J]. Front Oncol, 2023, 13: 1113389. DOI: 10.3389/fonc.2023.1113389.
- [33] LI JX, SU TS, GONG WF, et al. Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: A single-arm trial[J]. Hepatol Int, 2022, 16(5): 1179-1187. DOI: 10.1007/s12072-022-10396-7.
- [34] QIU H, KE SB, CAI GK, et al. An exploratory clinical trial of apatinib combined with intensity-modulated radiation therapy for patients with unresectable hepatocellular carcinoma[J]. Cancer Med, 2023, 12(1): 213-222. DOI: 10.1002/cam4.4900.
- [35] CHEN B, LI YX, WANG L, et al. Phase II study of concurrent sorafenib and radiotherapy for advanced hepatocellular carcinoma with portal vein and/or hepatic vein tumor thrombosis[J]. Int J Radiat Oncol Biol Phys, 2021, 111(3s): S39. DOI: 10.1016/j.ijrobp.2021.07.112.
- [36] NING C, ZHANG X, WANG Y, et al. Radiation therapy with combination therapy of immune checkpoint inhibitors and antiangiogenic therapy for hepatocellular carcinoma [J]. Int J Radiat Oncol Biol Phys, 2023. DOI: 10.1016/j.ijrobp.2023.07.001. [Online ahead of print].
- [37] NING C, JIA J, ZHANG X, et al. Efficacy and safety of subsequent radiotherapy in patients with advanced-stage hepatocellular carcinoma treated with immune checkpoint inhibitors. [J]. Hepatobiliary Surg Nutr, 2023. [Online ahead of print].
- [38] FAN J, TANG ZY, YU YQ, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma[J]. Dig Surg, 1998, 15(6): 674-678. DOI: 10.1159/000018676.
- [39] TANG ZY, UY YQ, ZHOU XD, et al. Cytoreduction and se-

- quential resection for surgically verified unresectable hepatocellular carcinoma: Evaluation with analysis of 72 patients[J]. *World J Surg*, 1995, 19(6): 784-789. DOI: 10.1007/BF00299771.
- [40] ZHAO HT, SANG XT, RUI JA, et al. Analysis of curative effect of unresectable advanced liver cancer resection after descending stage[J]. *Acta Acad Med Sin*, 2009, 31(4): 503-505. DOI: 10.3881/j.issn.1000-503X.2009.04.024. 赵海涛, 桑新亭, 芮静安, 等. 不能手术切除的晚期肝癌降期后切除疗效分析[J]. *中国医学科学院学报*, 2009, 31(4): 503-505. DOI: 10.3881/j.issn.1000-503X.2009.04.024.
- [41] CHEN YJ. Current state and thinking of liver cancer conversion therapy[J]. *Chin J Pract Surg*, 2021, 41(3): 253-256, 261. DOI: 10.19538/j.cjps.issn1005-2208.2021.03.03. 陈亚进. 肝癌转化治疗现状与思考[J]. *中国实用外科杂志*, 2021, 41(3): 253-256, 261. DOI: 10.19538/j.cjps.issn1005-2208.2021.03.03.
- [42] KUBOTA K, AOKI T, KUMAMARU H, et al. Use of the National Clinical Database to evaluate the association between preoperative liver function and postoperative complications among patients undergoing hepatectomy[J]. *J Hepatobiliary Pancreat Sci*, 2019, 26(8): 331-340. DOI: 10.1002/jhbp.644.
- [43] IMAMURA H, SEYAMA Y, KOKUDO N, et al. One thousand fifty-six hepatectomies without mortality in 8 years [J]. *Arch Surg*, 2003, 138(11): 1198-1206;discussion1206. DOI: 10.1001/archsurg.138.11.1198.
- [44] YUAN SX, ZHOU WP. Progress and experience of transformation therapy for primary liver cancer[J]. *J Hepatobiliary Surg*, 2022, 30(3): 161-164, 168. DOI: 10.3969/j.issn.1006-4761.2022.03.002. 袁声贤, 周伟平. 原发性肝癌转化治疗的进展和体会[J]. *肝胆外科杂志*, 2022, 30(3): 161-164, 168. DOI: 10.3969/j.issn.1006-4761.2022.03.002.
- [45] PAYE F, JAGOT P, VILGRAIN V, et al. Preoperative chemoembolization of hepatocellular carcinoma: A comparative study[J]. *Arch Surg*, 1998, 133(7): 767-772. DOI: 10.1001/archsurg.133.7.767.
- [46] YANG J, TAO HS, CAI W, et al. Accuracy of actual resected liver volume in anatomical liver resections guided by 3-dimensional parenchymal staining using fusion indocyanine green fluorescence imaging[J]. *J Surg Oncol*, 2018, 118(7): 1081-1087. DOI: 10.1002/jso.25258.
- [47] MISE Y, HASEGAWA K, SATOU S, et al. How has virtual hepatectomy changed the practice of liver surgery? : Experience of 1194 virtual hepatectomy before liver resection and living donor liver transplantation[J]. *Ann Surg*, 2018, 268(1): 127-133. DOI: 10.1097/SLA.0000000000002213.
- [48] GRUTTADAURIA S, VASTA F, MINERVINI MI, et al. Significance of the effective remnant liver volume in major hepatectomies[J]. *Am Surg*, 2005, 71(3): 235-240.
- [49] XIONG JJ, ALTAF K, JAVED MA, et al. Meta-analysis of laparoscopic vs open liver resection for hepatocellular carcinoma[J]. *World J Gastroenterol*, 2012, 18(45): 6657-6668. DOI: 10.3748/wjg.v18.i45.6657.
- [50] FU B, ZHANG JR, HAN PS, et al. Comparison of survival and post-operation outcomes for minimally invasive versus open hepatectomy in hepatocellular carcinoma: A systematic review and meta-analysis of case-matched studies [J]. *Front Oncol*, 2022, 12: 1021804. DOI: 10.3389/fonc.2022.1021804.
- [51] Alliance of Liver Cancer Conversion Therapy, Committee of Liver Cancer of the Chinese AntiCancer Association. Chinese expert consensus on conversion therapy in hepatocellular carcinoma(2021 edition) [J]. *Chin J Pract Surg*, 2021, 41(6): 618-632. DOI: 10.19538/j.cjps.issn1005-2208.2021.06.02. 中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版)[J]. *中国实用外科杂志*, 2021, 41(6): 618-632. DOI: 10.19538/j.cjps.issn1005-2208.2021.06.02.
- [52] OMATA M, CHENG AL, KOKUDO N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update[J]. *Hepatol Int*, 2017, 11(4): 317-370. DOI: 10.1007/s12072-017-9799-9.
- [53] European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma[J]. *J Hepatol*, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
- [54] CHEN MS, LI JQ, ZHENG Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma[J]. *Ann Surg*, 2006, 243(3): 321-328. DOI: 10.1097/01.sla.0000201480.65519.b8.
- [55] KUDO M, HASEGAWA K, KAWAGUCHI Y, et al. A multicenter randomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF trial): Analysis of overall survival[J]. *J Clin Oncol*, 2021, 39: 4093. DOI: 10.1200/JCO.2021.39.15_SUPPL.4093.
- [56] LI L, ZHANG JL, LIU XH, et al. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: A meta-analysis[J]. *J Gastroenterol Hepatol*, 2012, 27(1): 51-58. DOI: 10.1111/j.1440-1746.2011.06947.x.
- [57] CHO YK, KIM JK, KIM MY, et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies[J]. *Hepatology*, 2009, 49(2): 453-459. DOI: 10.1002/hep.22648.
- [58] WEINSTEIN JL, AHMED M. Percutaneous ablation for hepatocellular carcinoma[J]. *AJR Am J Roentgenol*, 2018, 210(6): 1368-1375. DOI: 10.2214/AJR.17.18695.
- [59] PENG ZW, ZHANG YJ, CHEN MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: A prospective randomized trial[J]. *J Clin Oncol*, 2013, 31(4): 426-432. DOI: 10.1200/JCO.2012.42.9936.
- [60] NAULT JC, SUTTER O, NAHON P, et al. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations[J]. *J Hepatol*, 2018, 68(4): 783-797. DOI: 10.1016/j.jhep.2017.10.004.
- [61] CHENG PL, WU PH, KAO WY, et al. Comparison of local

- ablative therapies, including radiofrequency ablation, microwave ablation, stereotactic ablative radiotherapy, and particle radiotherapy, for inoperable hepatocellular carcinoma: A systematic review and meta-analysis[J]. *Exp Hematol Oncol*, 2023, 12(1): 37. DOI: 10.1186/s40164-023-00400-7.
- [62] AHMED M, SOLBIATI L, BRACE CL, et al. Image-guided tumor ablation: Standardization of terminology and reporting criteria: A 10-year update[J]. *Radiology*, 2014, 273(1): 241-260. DOI: 10.1148/radiol.14132958.
- [63] GLAZER DI, TATLI S, SHYN PB, et al. Percutaneous image-guided cryoablation of hepatic tumors: Single-center experience with intermediate to long-term outcomes[J]. *AJR Am J Roentgenol*, 2017, 209(6): 1381-1389. DOI: 10.2214/AJR.16.17582.
- [64] LEE EW, WONG D, PRIKHODKO SV, et al. Electron microscopic demonstration and evaluation of irreversible electroporation-induced nanopores on hepatocyte membranes[J]. *J Vasc Interv Radiol*, 2012, 23(1): 107-113. DOI: 10.1016/j.jvir.2011.09.020.
- [65] KUMAR M, PANDA D. Role of supportive care for terminal stage hepatocellular carcinoma[J]. *J Clin Exp Hepatol*, 2014, 4(Suppl 3): S130-S139. DOI: 10.1016/j.jceh.2014.03.049.
- [66] HAMMAD AY, ROBBINS JR, TURAGA KK, et al. Palliative interventions for hepatocellular carcinoma patients: Analysis of the National Cancer Database[J]. *Ann Palliat Med*, 2017, 6(1): 26-35. DOI: 10.21037/apm.2016.11.02.
- [67] CHENG Y, HUA HQ. Research progress on anti-hepatoma mechanisms and clinical application of β -elemene[J]. *Chin Clin Oncol*, 2017, 22(10): 950-953.
成远, 华海清. 榄香烯治疗原发性肝癌的研究进展[J]. *临床肿瘤学杂志*, 2017, 22(10): 950-953.
- [68] LU DP, WANG YQ, ZHAO WL, et al. Clinical study of Kanglaite combined with hepatic arterial chemoembolization in the treatment of liver cancer[J]. *The World Clin Medicine*, 2017, 11(5): 70.
路大鹏, 王玉强, 赵卫林, 等. 康莱特联合肝动脉化疗栓塞术治疗肝癌的临床研究[J]. *世界临床医学*, 2017, 11(5): 70.
- [69] TIAN HP, GAO HM, YANG P, et al. Meta-analysis on efficacy and safety of cinobufacini combined with transcatheter arterial chemoembolization for primary liver cancer[J]. *World Chin Med*, 2016, 11(10): 2151-2155. DOI: 10.3969/j.issn.1673-7202.2016.10.058.
田怀平, 高蕙敏, 杨萍, 等. 华蟾素联合肝动脉化疗栓塞治疗原发性肝癌的疗效与安全性 Meta 分析[J]. *世界中医药*, 2016, 11(10): 2151-2155. DOI: 10.3969/j.issn.1673-7202.2016.10.058.
- [70] CHEN NJ, JIN Y, LAI YQ, et al. Xiaoaiping combined with chemotherapy in the treatment of 22 cases of advanced liver cancer[J]. *J Tradit Chin Med*, 2005, 46(6): 444-445. DOI: 10.13288/j.11-2166/r.2005.06.030.
陈乃杰, 金源, 赖义勤, 等. 消癌平联合化疗治疗中晚期肝癌 22 例[J]. *中医杂志*, 2005, 46(6): 444-445. DOI: 10.13288/j.11-2166/r.2005.06.030.
- [71] TONG GW, GAO P. Clinical study on Xiaoaiping Injection combined with Elemene Injection in treatment of advanced primary hepatocellular carcinoma[J]. *Drugs Clin*, 2016, 31(5): 691-695. DOI: 10.7501/j.issn.1674-5515.2016.05.029.
童光武, 高鹏. 消癌平注射液联合榄香烯注射液治疗中晚期原发性肝癌的临床研究[J]. *现代药物与临床*, 2016, 31(5): 691-695. DOI: 10.7501/j.issn.1674-5515.2016.05.029.
- [72] LIU DM. Transcatheter arterial chemoembolization combined with hepatic arterial chemoembolization Curative effect observation of treating advanced liver cancer[J/CD]. *J Clin Med Lit*, 2016, 3(2): 235-236. DOI: 10.16281/j.cnki.jocml.2016.02.028.
刘冬梅. 肝复乐胶囊联合肝动脉栓塞化疗治疗晚期肝癌的疗效观察[J/CD]. *临床医药文献电子杂志*, 2016, 3(2): 235-236. DOI: 10.16281/j.cnki.jocml.2016.02.028.
- [73] YANG YX, HE X, WEN JX, et al. Meta-analysis on aidi injection combined with transcatheter arterial chemoembolization in treatment of primary liver cancer[J]. *Eval Anal Drug Use Hosp China*, 2016, 16(12): 1588-1593. DOI: 10.14009/j.issn.1672-2124.2016.12.002.
杨玉雪, 何璇, 文建霞, 等. 艾迪注射液与肝动脉栓塞化疗联合治疗原发性肝癌的系统评价[J]. *中国医院用药评价与分析*, 2016, 16(12): 1588-1593. DOI: 10.14009/j.issn.1672-2124.2016.12.002.
- [74] SUN Y, QIN S, LI W, et al. A randomized, double-blinded, phase III study of icaritin versus huachashu as the first-line therapy in biomarker-enriched HBV-related advanced hepatocellular carcinoma with poor conditions: Interim analysis result[J]. *J Clin Oncol*, 2021, 39(15 Suppl): 4077.
- [75] BRUIX J, QIN SK, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. *Lancet*, 2017, 389(10064): 56-66. DOI: 10.1016/S0140-6736(16)32453-9.
- [76] ZHU AX, FINN RS, EDELINE J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial[J]. *Lancet Oncol*, 2018, 19(7): 940-952. DOI: 10.1016/S1470-2045(18)30351-6.
- [77] FINN RS, RYOO BY, MERLE P, et al. Pembrolizumab As second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial[J]. *J Clin Oncol*, 2020, 38(3): 193-202. DOI: 10.1200/JCO.19.01307.
- [78] QIN S, CHEN Z, FANG W, et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study[J]. *J Clin Oncol*, 2022, 40(4 Suppl): 383.
- [79] QIN SK, LI Q, GU SZ, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial[J]. *Lancet Gastroenterol Hepatol*, 2021, 6(7): 559-568. DOI: 10.1016/S2468-1253(21)00109-6.
- [80] ZHU AX, KANG YK, YEN CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma

- noma and increased α -fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. *Lancet Oncol*, 2019, 20(2): 282-296. DOI: 10.1016/S1470-2045(18)30937-9.
- [81] KUDO M, FINN RS, QIN SK, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. *Lancet*, 2018, 391(10126): 1163-1173. DOI: 10.1016/S0140-6736(18)30207-1.
- [82] IKEDA M, KOBAYASHI M, TAHARA M, et al. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib[J]. *Expert Opin Drug Saf*, 2018, 17(11): 1095-1105. DOI: 10.1080/14740338.2018.1530212.
- [83] POSTOW MA, SIDLOW R, HELLMANN MD. Immune-related adverse events associated with immune checkpoint blockade[J]. *N Engl J Med*, 2018, 378(2): 158-168. DOI: 10.1056/NEJMra1703481.
- [84] THOMPSON JA, SCHNEIDER BJ, BRAHMER J, et al. NCCN guidelines insights: Management of immunotherapy-related toxicities, version 1.2020[J]. *J Natl Compr Canc Netw*, 2020, 18(3): 230-241. DOI: 10.6004/jnccn.2020.0012.
- [85] BARROSO-SOUSA R, BARRY WT, GARRIDO-CASTRO AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis[J]. *JAMA Oncol*, 2018, 4(2): 173-182. DOI: 10.1001/jamaoncol.2017.3064.
- [86] GEUKES FOPPEN MH, ROZEMAN EA, VAN WILPE S, et al. Immune checkpoint inhibition-related colitis: Symptoms, endoscopic features, histology and response to management[J]. *ESMO Open*, 2018, 3(1): e000278. DOI: 10.1136/esmoopen-2017-000278.
- [87] DELANOY N, MICHOT JM, COMONT T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: A descriptive observational study[J]. *Lancet Haematol*, 2019, 6(1): e48-e57. DOI: 10.1016/S2352-3026(18)30175-3.